Year of Publication

2021

Degree Name

Doctor of Philosophy (PhD)

Document Type

Doctoral Dissertation

College

Pharmacy

Department

Pharmaceutical Sciences

First Advisor

Dr. Patrick Marsac

Second Advisor

Dr. Younsoo Bae

Abstract

The successful delivery of chemical compounds for the purpose of therapeutic treatments and prophylactics is a substantial undertaking in modern drug development. Notably, the adoption of high throughput screening techniques has led to the proliferation of poorly water soluble and/or highly potent molecules which further complicate development activities. Spray dried amorphous solid dispersions are an increasingly important formulation strategy to overcome solubility issues while wet granulation approaches are the method of choice for the preparation of highly potent APIs in oral solid dosage forms.

A common connection between these critical techniques is their reliance on solvent-based processing that can often result in unexpected outcomes on product quality and performance. Solvent choice has been shown to influence API form, habit, stabilizing interactions, and physical and chemical properties of drug product intermediates, which requires greater understanding. The objective of this dissertation is to provide a general overview and assessment of the role of solvents in the important methods of spray dried dispersions (SDDs) and highly potent compounds by wet shear granulations (HP-WSG) to address concerns related to poorly soluble and/or highly potent APIs.

Light scattering (LS) and dilute solution viscometry (DSV) techniques have been utilized to assess critical drug-polymer-solvent interactions in the solution state and explore the mechanisms by which solvent choice may influence SDD physical stability. Next, solid-state characterization techniques were leveraged to understand how the interplay between wet granulation processing parameters, API physical form, and environmental moisture may dictate chemical stability issues of a highly potent API. Conclusions and future work are presented with next steps that can be pursued in expanding our knowledge of complex multi-component solutions which are frequently encountered in pharmaceutical development.

Digital Object Identifier (DOI)

https://doi.org/10.13023/etd.2021.011

Funding Information

Pharmaceutical Research and Manufacturers of America (PhRMA) Predoctoral Fellowship in Pharmaceutics, Jan 2018 - Dec 2020

Center for Pharmaceutical Development (CPD), 2016-2020

US World Meds, LLC, May 2019 - May 2020)

Available for download on Friday, February 11, 2022

Share

COinS